September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Visual Acuity and Inflammation Outcomes in Intermediate Uveitis
Author Affiliations & Notes
  • Elliot Crane
    Rutgers New Jersey Medical School, Pine Brook, New Jersey, United States
  • May Shum
    Rutgers New Jersey Medical School, Pine Brook, New Jersey, United States
  • Jason S. Kim
    Rutgers New Jersey Medical School, Pine Brook, New Jersey, United States
  • Eliott Kim
    Rutgers New Jersey Medical School, Pine Brook, New Jersey, United States
  • Alexander B Crane
    Rutgers New Jersey Medical School, Pine Brook, New Jersey, United States
  • David S Chu
    Rutgers New Jersey Medical School, Pine Brook, New Jersey, United States
    Metropolitan Eye Research and Surgery Institute, Palisades Park, New Jersey, United States
  • Footnotes
    Commercial Relationships   Elliot Crane, None; May Shum, None; Jason Kim, None; Eliott Kim, None; Alexander Crane, None; David Chu, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 3312. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Elliot Crane, May Shum, Jason S. Kim, Eliott Kim, Alexander B Crane, David S Chu; Visual Acuity and Inflammation Outcomes in Intermediate Uveitis. Invest. Ophthalmol. Vis. Sci. 2016;57(12):3312.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To analyze the correlation between ocular inflammation, visual acuity, and disease treatment in subjects with intermediate uveitis and pars planitis (IU).

Methods : This is a retrospective cohort study. Billing records from a uveitis specialist in New Jersey were used to identify 45 subjects with intermediate uveitis and pars planitis seen between April of 2003 and February of 2015. 8 subjects met exclusion criteria of less than 6 months of follow up. Trends in visual acuity (VA) were calculated via modified logMAR notation. Inflammation was considered active when a grade of 1+ or worse was assigned to anterior chamber cell or flair, or vitreous cell or haze. Any discrete period of active inflammation between quiescent periods was considered a peak of disease recurrence; the number of these per year of subject follow up are peaks per year (PPY). Calculations were done using Microsoft Excel Version 14.0.1762.5000, MATLAB version 7.12.0.635. Fisher’s exact tests done with GraphPad Software 2015; P<0.05 was considered significant.

Results : Thirty-seven subjects were identified with intermediate uveitis or pars planitis (16 male, 21 female, mean age 38 +/- 20 years at first visit, mean follow up time 4.6 +/- 3.3 years). 26 (70%) were treated with methotrexate, 8 (22%) were treated with Humira, and 7 (19%) were treated with cellcept. The right eye (RE) and left eye (LE) improved by an average of 0.31 (+/- 6.0 standard deviation [SD]) and 0.77 (+/- 5.1 SD) lines of vision, respectively. 20 (54%) subjects had a worse VA during their final visit in at least one eye than during their initial visit; these subjects experienced significantly more glaucoma (4.9 times, P<0.05), but similar rates of macular edema and cataracts (p>0.05) than subjects with unchanged or improved VAs in both eyes. Only 3 (8.1%) subjects had a worse VA during their final visit in both eyes than during their initial visit. 19 (51%) REs and 24 (65%) LEs experienced peaks of disease recurrence; of those, the REs experienced a mean of 0.73 (+/- 0.52 SD) PPY with each peak lasting 84 (+/- 107 SD) days and the LEs experienced a mean of 0.79 (+/- 0.66 SD) PPY with each peak lasting 83 (+/- 160 SD) days.

Conclusions : Ocular inflammation and peaks of disease recurrence in patients with IU can be effectively managed with aggressive antiinflammatory treatment with good visual outcomes.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×